Ontology highlight
ABSTRACT: Introduction
In rare diseases, registry-based studies can be used to provide natural history data pre-approval and complement drug efficacy and/or safety knowledge post-approval.Objective
The objective of this study was to investigate the opinion of stakeholders about key aspects of rare disease registries that are used to support regulatory decision making and to compare the responses of employees from industry to other stakeholders.Methods
A web-based survey was used to gauge the importance of (1) common data elements (including safety outcomes), (2) data quality and (3) governance aspects that are generic across different rare diseases. The survey included 47 questions. The data were collected in the period April-October 2019.Results
Seventy-three respond
SUBMITTER: Jonker CJ
PROVIDER: S-EPMC8279983 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature